Here is my current top ranked sectors from amongst the 60 that I track:

Data from Best Stocks Now App

The pharmaceutical sector, as seen by the SPDR S&P Pharmaceuticals (XPH) ETF, is up over 54% year to date, while biotechs (iShares Nasdaq Biotechnology Index (IBB)) are up 52%, and the Internet sector (First Trust DJ Internet Index Fund (FDN)) is up 42%.

That brings me back to a stock that I own at Gunderson Capital Management, Akorn.

Data from Best Stocks Now App

The company, which is headquartered in Lake Forest, Ill., develops pharmaceuticals in specialty areas such as ophthalmology, hospital drugs and injectables.

Earnings growth over the last five years has averaged about 32% per year and the company is expected to continue to grow by about 20% per year over the next five years.

The old adage goes that from little acorns grow mighty oaks. Akorn is a $2 billion company now. When I first started following AKRX it was only a $1 billion company. Who knows how much bigger it is going to get? It was a little acorn, now it is a much larger acorn. Will it ever be a mighty oak? I don't know, but it is sure doing well right now and I'm very happy so far with my position in the stock.

While earnings growth is nice, I demand the stocks that I own be top performers as it relates to the rest of the stocks in the market. I like to invest in leaders and not laggards.

Performance

Data from Best Stocks Now App

This stock has been a terrific performer. Over the last 10 years the stock has delivered almost 27% per year to investors while the market has delivered 5.5% per year.

Over the last five years AKRX has delivered almost 62% per year while the market has delivered 15% per year. Over the last three years AKRX has continued to deliver 58% per year while the market has delivered 14%. And over the last 12 months AKRX is up 73% while the market is only up 32%!

When I compare the performance of AKRX against the more than 3,600 stocks that I track, Akorn gets a performance grade of 'A+'. It is one of the rare stocks that gets such a high grade. It also gets a momentum grade of 'A'.

If you liked this article you might like

Teva, Mylan Seen to Stay on M&A Sidelines

Merger Buzz Drives Akorn to Top of Health Chart in April

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

European Stocks High on French Perfume and Trump Bump

Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More